卢奕教学副教授、博士生导师


luy3@sustech.edu.cn
生物楼507
进入个人主页返回到师资列表
个人简介卢奕，博士，现为南方科技大学副教授，博士生导师。美国肿瘤研究学会会员、美国骨及矿物质研究学会会员、中国免疫学会终身会员、中国生物医学技术协会转化医学分会理事、中国抗癌协会肿瘤转移专业委员会委员、肿瘤微环境专业委员会委员。自2002年起至2011年初回国前在美国密西根大学和匹兹堡大学肿瘤中心做博士后和研究员。作为研究骨干参与完成多项美国DOD和NIH研究项目。回国后，曾任广西南宁市****；广西医科大学转化医学研究中心副主任、教授、博士生导师；长寿与老年相关疾病教育部重点实验室副主任。作为项目主持人，主持多项国家及省部级科研项目，2011年，2012年，2017年和2019年多次获得国家自然科学基金面上项目；2012年获得广西自然基金回国重点项目和教育厅重点项目各1项；2017年获得深圳市科创委学科布局项目1项和自由探索项目1项。已完成国家973重大科学研究项目子课题1项（排名第二），主持并完成天津市应用基础研究重点项目1项，国自然面上项目2项。作为第二负责人参加国家自然科学基金重点项目研究1项；广西自治区重大研究项目1项以及平台建设项目多项。担任NSFC评审委员。研究成果多次获奖，2007年获得美国骨疾病研究学会颁发的青年****奖，并多次获得省部级科技进步奖。多年主讲本科生《医学免疫学》、《分子生物学》、《临床免疫及诊断》，研究生《分子生物学进展》、《高级免疫学》。指导和培养博士研究生6名，硕士研究生12名。发表论文70余篇，其中SCI收录论文60篇。近五年以第一作者和/或通讯作者发表研究论文15篇。拥有美国发明专利1项，已授权中国专利3项。研究方向：肿瘤微环境与肿瘤转移、肿瘤血管形成与肿瘤免疫。
研究领域肿瘤微环境与肿瘤转移
肿瘤预警标志物
肿瘤血管形成与肿瘤免疫



教育背景1980—1984：学士，南开大学生物系遗传专业
1987—1990：硕士，南开大学分子生物学研究所生物与分子生物学专业
2004—2007：博士，天津医科大学免疫学专业

工作经历1984—1987：天津医科大学计划生育研究所助理研究员
1990—2002 ：天津医科大学医学检验学院讲师/副教授/硕士生导师
2002—2003：美国密歇根大学肿瘤研究中心研究员
2003—2010：天津医科大学免疫学教授/硕士生和博士生导师
2004—2010：美国匹兹堡大学医学院病理系研究员
2011—2016：广西医科大学****，“长寿与老年相关疾病”教育部重点实验室副主任/教授；转化医学研究中心副主任/教授
2015—至今：广西南宁市特聘专家
2017—至今：南方科技大学医学院/研究副教授/教学副教授

获奖情况及荣誉2009- Scholar-in-Training Award, AACR
2007- Young Investigator Travel Award, ASBMR
2005- Scholar-in-Training Award, AACR
2003- Second class of Tianjia Technology Progress Award, China
2003- Third class of Tianjin Technology Progress Award, China
2000- Third class of Tianjin Technology Progress Award, China
1997- Third class of Tianjin Technology Progress Award, China
1994- Third class of Xianyi Zhu Medical Award, China

近年代表文章Yun C, Chang M, Hou G, Lan T, Yuan H, Su Z, Zhu D, Liang W, Li Q, Zhu H, Zhang J,Lu Y*, Deng J*, Guo H*. Mangiferin suppresses allergic asthma symptoms by decreased Th9 and Th17 responses and increased Treg response.Molecular Immunology. 2019, 114:233-242.
Guo H, Wang F, Diao Y, Zhang Z, Chen Q, Qian CN, Keller ET, Zhang J*,Lu Y*. Knockdown of Notch1 inhibits nasopharyngeal carcinoma cell growth and metastasis via downregulation of CCL2, CXCL16, and uPA.Molecular Carcinogenesis.2019, 58:1886-1896.
Liang W, Wang F, Chen Q, Dai J, Escara-Wilke J, Keller ET, Zimmermann J, Hong N,Lu Y*, Zhang J*.Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone.J Cancer Res Clin Oncol.2019 Jun 6. 145:1999-2012. Doi: 10.1007/s00432-019-02950-y.
Wang W, Yang X, Dai J,Lu Y, Zhang J, and Keller E*. Prostate cancer promotes a vicious cycle of bone metastasis progression through inducing osteocytes to secrete GDF15 that stimulates prostate cancer growth and invasion.Oncogene, 2019, Feb 12. 38（23）：4540-45559. doi: 10.1038/s41388-019-0736-3
Su W, Wang L, Niu F, Zou L, Guo C, Wang Z, Yang X, Wu J,Lu Y, Zhang J, Beer DG, Yang Z, Chen G.LINC00857knockdown inhibits cell proliferation and induces apoptosis via involving STAT3 and MET oncogenic proteins in esophageal adenocarcinoma.Aging-US. 2019 May 13;11(9):2812-2821. doi: 10.18632/aging.101953.
Junlin Shi, Lihui Wang, Chunlin Zou, Yudui Xia, Siyuan Qin, Evan Keller, Atsushi Mizokami, Jian Zhang*,Yi Lu*. Tumor microenvironment promotes prostate cancer cell dissemination via the Akt/mTOR pathway.Oncotarget, 2018, 9(10):9206-18.
Xia Y, Liu X, Zou C, Feng S, Guo H, Yang Y, Lei Y, Zhang J*, andLu Y*. Garcinone C exerts antitumor activity by modulating the expression of ATR/Stat3/4E?BP1 in nasopharyngeal carcinoma cells.Oncology Reports, 2018, 39:1485-93.
Jie Meng, Li-Hui Wang, Chun-Lin Zou, Sheng-Ming Dai, Jian Zhang*,Yi Lu*. C10orf116 Gene Copy Number Loss in Prostate Cancer: Clinicopathological Correlations and Prognostic Significance.Med Sci Monit2017; 23:5176-5183. DOI: 10.12659/MSM.906680.
Pascal LE,Masoodi KZ,Liu J1,Qiu X,Song Q,Wang Y,Zang Y,Yang T,Wang Y,Rigatti LH,Chandran U,Colli LM,Vencio RZN,Lu Y,Zhang J,Wang Z. Conditional deletion of ELL2 induces murine prostate intraepithelial neoplasia.J Endocrinol.2017 Nov;235(2):123-136. doi: 10.1530/JOE-17-0112.
Chunlin Zou,Yi Lu, Xiahong Teng, Shuyan Wang, Xiaoting Sun, Fen Huang, Guannan Shu, Xin Huang, Hongwei Guo, Zhiguo Chen, Jian Zhang, Yu Alex Zhang. MRI tracking of autologous pancreatic progenitor-derived insulin-producing cells in monkeys.Rep.2017, 7(1):2505.
Wenchu Wang, Lihui Wang, Atsushi Mizokami, Junlin Shi, Chunlin Zou, Jinlu Dai, Evan T. Keller,Yi Lu*and Jian Zhang*. Down-regulation ofE-cadherin enhances prostate cancer chemoresistance viaNotch signaling.Chinese Journal of Cancer, 2017; 36:35
Yong Lei, Yanhua Yi, Yang Liu, Xia Liu, Evan T. Keller, Chao-Nan Qian, Jian ZhangZ* andLu Y*.Metformin targets multiple signaling pathways in cancer.Chinese Journal of Cancer, 2017, 36 (1):17.
Qiuyan Chen, Siyuan Qin, Yang Liu, Minghuang Hong, Chao-Nan Qian, Evan T Keller, Zhang J,Lu Y*.IGFBP-6 is a novel nasopharyngeal carcinoma prognostic biomarker.Oncotarget,2016， Oct 18;7(42):68140-68150.
Jing Li, Xin Yang, Hao Guan, Atsushi Mizokami, Evan T. Keller, Xiaozhen Xu, Xia Liu, Jiyong Tan, Longyuan Hu,Lu Y*, Jian Zhang. Exosome-derived microRNAs contribute to prostate cancer chemoresistance.International Journal of Oncology, 2016，49:838-846.
Guihui Qin, Min Luo, Junze Chen, Yiwu Dang, Gang Chen, Li Li, Jing Zeng,Lu Y, Jie Yang. Reciprocal activation between MMP-8 and TGF-β1 stimulates EMT and malignant progression of hepatocellular carcinoma.Cancer Letters, 2016 Apr 28;374(1):85-95. doi: 10.1016/j.canlet.2016.02.001.
YuZhu,ChunlinZou,ZheZhang,ChaonanQian,XinYang,JunlinShi,YuduiXia,Zhang J,Lu Y*.MEKinhibitordiminishesnasopharyngealcarcinoma(NPC)cellgrowthand NPC-induced osteoclastogenesisviamodulatingCCL2andCXCL16expression.TumorBiology, 2015, 36(11):8811-8. doi: 10.1007/s13277-015-3595-8.
ShaHe,Lu Y,XiaLiu,XinHuang,EvanKeller, Chao-NanQian,Zhang Wnt3a:functionandimplicationincancer.ChineseJournalofCancer, 2015, 34(3):50. DOI: 10.1186/s40880-015-0052-4
Hongwei Guo, Xiaolin Zhou,Lu Y, Liye Xie, Qian Chen, Evan T. Keller, Qian Liu, Qinghua Zhou , and Zhang Translational progress on tumor biomarkers.Thoracic Cancer.27 JUL 2015, DOI: 10.1111/1759-7714.12294
Huajiao Guo,Lu Y, Jianhua Wang, Xia Liu, Evan T. Keller, Qian Liu, Qinghua Zhou, Jian Zhang, Targeting Notch Signaling Pathway in Cancer Therapeutics.Thoracic Cancer, 2014, 5. 473-86 .
Lu Y, Gu X, Chen L, Yao Z, Song J, Niu X, Xiang R, Cheng T, Qin Z, Deng W, Li LY.Interferon-γ produced by tumor-infiltrating NK cells and CD4+T cells downregulates TNFSF15 expression in vascular endothelial cells.Angiogenesis. 2014 Jul;17(3):529-40.
Lu Y, Zhang Z, Yan Z, Chen L, Deng W, Lotze M, Wang Z, Lin X, Li LY. Restoration of p53 Functions in Breast Cancer Cells in vivo with Recombinant GnRH-p53 Fusion Protein Enhances 5-Fluorouracil Anticancer Efficacy.Apoptosis， Oct;18(10):1214-23，
Zhang J,Lu Y, and Pienta KJ. Multiple roles of CC chemokine ligand 2 (CCL2) in promoting prostate cancer growth.J National Cancer Institute102(8):522-8, 2010.
Lu Y*,Chen Q, Corey E, Xie W, Fan J, Mizokami A, and Zhang J. Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone.Clin Exp Metastasis26(2):161-9, 2009.
Lu Y, Nie DB, Witt WT, Chen Q, Shen M, Xie H, Lai L, Dai Y, Zhang J. Expression of fat-1 gene diminishes prostate cancer growth in vivo through enhancing apoptosis and inhibiting GSK-3β phosphorylation.Molecular Cancer Therapeutics 7(10):3203-11,
Lu Y,Cai Z, Xiao G, Keller ET, Mizokami A, Yao Z, Roodman GD, Zhang J. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption.Cancer Res67:3646-53, 2007.
Lu Y,Xiao G, Galson DL, Nishio Y, Mizokami A, Yao Z, and Zhang J. PTHrP-induced MCP-1 production by human bone marrow endothelial cells promotes osteosteoclastast differentiation and prostate cancer cell proliferation and invasion in vitro.Int J of Cancer121:724-733, 2007.
Lu Y,Cai Z, Galson DL, Xiao G, Liu YL, George D, Melhem MF, Yao Z and Zhang J. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for PCa growth and invasion.Prostate66:1311-8, 2006.